225 related articles for article (PubMed ID: 28535337)
1. Overall Structural Model of NS5A Protein from Hepatitis C Virus and Modulation by Mutations Confering Resistance of Virus Replication to Cyclosporin A.
Badillo A; Receveur-Brechot V; Sarrazin S; Cantrelle FX; Delolme F; Fogeron ML; Molle J; Montserret R; Bockmann A; Bartenschlager R; Lohmann V; Lippens G; Ricard-Blum S; Hanoulle X; Penin F
Biochemistry; 2017 Jun; 56(24):3029-3048. PubMed ID: 28535337
[TBL] [Abstract][Full Text] [Related]
2. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.
Verdegem D; Badillo A; Wieruszeski JM; Landrieu I; Leroy A; Bartenschlager R; Penin F; Lippens G; Hanoulle X
J Biol Chem; 2011 Jun; 286(23):20441-54. PubMed ID: 21489988
[TBL] [Abstract][Full Text] [Related]
3. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.
Chatterji U; Lim P; Bobardt MD; Wieland S; Cordek DG; Vuagniaux G; Chisari F; Cameron CE; Targett-Adams P; Parkinson T; Gallay PA
J Hepatol; 2010 Jul; 53(1):50-6. PubMed ID: 20451281
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
5. A Proline-Tryptophan Turn in the Intrinsically Disordered Domain 2 of NS5A Protein Is Essential for Hepatitis C Virus RNA Replication.
Dujardin M; Madan V; Montserret R; Ahuja P; Huvent I; Launay H; Leroy A; Bartenschlager R; Penin F; Lippens G; Hanoulle X
J Biol Chem; 2015 Jul; 290(31):19104-20. PubMed ID: 26085105
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.
Arai M; Tsukiyama-Kohara K; Takagi A; Tobita Y; Inoue K; Kohara M
Biochem Biophys Res Commun; 2014 May; 448(1):56-62. PubMed ID: 24751518
[TBL] [Abstract][Full Text] [Related]
7. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
Garcia-Rivera JA; Bobardt M; Chatterji U; Hopkins S; Gregory MA; Wilkinson B; Lin K; Gallay PA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5113-21. PubMed ID: 22802259
[TBL] [Abstract][Full Text] [Related]
8. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
10. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
11. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
12. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
Hopkins S; Bobardt M; Chatterji U; Garcia-Rivera JA; Lim P; Gallay PA
Antimicrob Agents Chemother; 2012 Jul; 56(7):3888-97. PubMed ID: 22585215
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
[TBL] [Abstract][Full Text] [Related]
14. A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.
Grisé H; Frausto S; Logan T; Tang H
J Virol; 2012 May; 86(9):4811-22. PubMed ID: 22345441
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.
Rosnoblet C; Fritzinger B; Legrand D; Launay H; Wieruszeski JM; Lippens G; Hanoulle X
J Biol Chem; 2012 Dec; 287(53):44249-60. PubMed ID: 23152499
[TBL] [Abstract][Full Text] [Related]
16. Cyclophilin A allows the allosteric regulation of a structural motif in the disordered domain 2 of NS5A and thereby fine-tunes HCV RNA replication.
Dujardin M; Madan V; Gandhi NS; Cantrelle FX; Launay H; Huvent I; Bartenschlager R; Lippens G; Hanoulle X
J Biol Chem; 2019 Aug; 294(35):13171-13185. PubMed ID: 31315928
[TBL] [Abstract][Full Text] [Related]
17. NS5A--from obscurity to new target for HCV therapy.
Schmitz U; Tan SL
Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
[TBL] [Abstract][Full Text] [Related]
18. Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
Beldar S; Manimekalai MSS; Cho NJ; Baek K; Grüber G; Yoon HS
J Gen Virol; 2018 Feb; 99(2):194-208. PubMed ID: 29300159
[TBL] [Abstract][Full Text] [Related]
19. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
Imhof I; Simmonds P
J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
